Close Menu

NEW YORK – Scipher Medicine and Ambry Genetics said on Thursday that they have partnered to scale up the availability of Scipher's PrismRA blood-based molecular test to predict response to tumor necrosis factor inhibitor (TNFi) therapies in rheumatoid arthritis patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Nov
10
Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.